| Name | Title | Contact Details |
|---|
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.
Samsung Biologics is the most qualified worlds leading Contract Development, Manufacturing and Research Organization, committed to quality-driven development, manufacturing of biopharmaceutical products.
BASi provides world-class research to the pharmaceutical industry worldwide. Established in 1974, we offer an extensive array of contract laboratory services and also manufacture more than 30 different scientific instruments. At BASi we focus on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market.
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.